Glaukos (GKOS)_个股概要_股票价格_行情走势图

自选
模拟交易
选股器
热力图
机构追踪

美股市场个股详情

GKOS Glaukos

添加自选

98.910
+2.910+3.03%

收盘价 05/01 16:00 (美东)

97.000
-1.910-1.93%

盘后 18:58 (美东)

49.64亿总市值-35579市盈率TTM

全部分时

5日
日K
周K
月K
季K
年K

资金分布

单位: --

资金流向

实时日周月

暂无数据

新闻

Moomoo AI

01/21 22:51

Glaukos' revenue growth is the market's focus due to its unprofitability. The 88% share price gain is solid, not standout. Market sentiment is lukewarm, hinting at potential stronger growth trends. Recent sentiment is positive due to strong share price momentum.

Investors Bid Glaukos (NYSE:GKOS) up US$137m Despite Increasing Losses YoY, Taking One-year Return to 88%

Meltyy

2023/12/19 15:33

PDUFA Update…

Last week’s PDUFAs:
$Arcutis Biotherapeutics(ARQT.US)$ :

Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$默沙东(MRK.US)$ : Approved 12/15

• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos(GKOS.US)$ : Approved 12/14

• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$默沙东(MRK.US)$ : Approved ...

Meltyy

2023/12/04 15:48

PDUFA Events for December 2023

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics(CRSP.US)$$福泰制药(VRTX.US)$$OptiNose(OPTN.US)$$Arcutis Biotherapeutics(ARQT.US)$$Calliditas Therapeutics(CALT.US)$$bluebird bio(BLUE.US)$$Glaukos(GKOS.US)$$Ionis Pharmaceuticals(IONS.US)$$安进(AMGN.US)$$默沙东(MRK.US)$

Moomoo AI

2023/11/03 19:30

Glaukos' stock carries risk due to losses and high debt, despite cash reserves. The absence of EBIT level profits and free cash flow make sustainability questionable. Investors should proceed with caution.